Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Expects Zyprexa Sales To Flatten During Bristol Abilify Launch In Q4

Executive Summary

Lilly is preparing for a temporary slowdown in Zyprexa growth during the introduction of Bristol-Myers Squibb's schizophrenia drug Abilify
Advertisement

Related Content

Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk
VA Antipsychotic Diabetes Risk Studies Continue; First Report Helps Zyprexa
Pfizer Pays Back Lilly: Geodon Promotions Focus On Zyprexa Diabetes Risk
J&J Finalizing Risperdal Consta Resubmission; Approval Possible By Year-End
From The Year-End Conference Calls....
Bristol Abilify Safety Profile Will Be Focus; Novel Mechanism May Help
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Bristol Abilify To Launch In Late November; Antipsychotic Approved Nov. 15
Lilly Cialis Using Alternate Manufacturing Facilities For 2nd Half 2003 Launch
Advertisement
UsernamePublicRestriction

Register

PS040692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel